MX2023015076A - Metodo para preparar un compuesto radioetiquetado [18f] con bajo contenido de agua durante la etapa de etiquetado. - Google Patents

Metodo para preparar un compuesto radioetiquetado [18f] con bajo contenido de agua durante la etapa de etiquetado.

Info

Publication number
MX2023015076A
MX2023015076A MX2023015076A MX2023015076A MX2023015076A MX 2023015076 A MX2023015076 A MX 2023015076A MX 2023015076 A MX2023015076 A MX 2023015076A MX 2023015076 A MX2023015076 A MX 2023015076A MX 2023015076 A MX2023015076 A MX 2023015076A
Authority
MX
Mexico
Prior art keywords
water content
preparing
radio
sup
low water
Prior art date
Application number
MX2023015076A
Other languages
English (en)
Spanish (es)
Inventor
Alexander Jackson
Torgrim Engell
Graeme Mcrobbie
Alan Clarke
Julian Grigg
Imtiaz Ahmed Khan
Kristine Wikene
Jonathan Shales
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of MX2023015076A publication Critical patent/MX2023015076A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/007—Steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
MX2023015076A 2021-06-16 2022-06-16 Metodo para preparar un compuesto radioetiquetado [18f] con bajo contenido de agua durante la etapa de etiquetado. MX2023015076A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2108605.3A GB202108605D0 (en) 2021-06-16 2021-06-16 Effect of water content
PCT/EP2022/066483 WO2022263594A1 (en) 2021-06-16 2022-06-16 Method for preparing an [18f] radiolabelled compound with low water content during labelling step

Publications (1)

Publication Number Publication Date
MX2023015076A true MX2023015076A (es) 2024-01-18

Family

ID=76954450

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023015076A MX2023015076A (es) 2021-06-16 2022-06-16 Metodo para preparar un compuesto radioetiquetado [18f] con bajo contenido de agua durante la etapa de etiquetado.

Country Status (12)

Country Link
US (2) US20240366808A1 (cg-RX-API-DMAC7.html)
EP (1) EP4355715A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024522770A (cg-RX-API-DMAC7.html)
KR (1) KR20240021888A (cg-RX-API-DMAC7.html)
CN (1) CN117500773A (cg-RX-API-DMAC7.html)
AU (1) AU2022294052A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023026514A2 (cg-RX-API-DMAC7.html)
CA (1) CA3223802A1 (cg-RX-API-DMAC7.html)
GB (1) GB202108605D0 (cg-RX-API-DMAC7.html)
IL (1) IL308917A (cg-RX-API-DMAC7.html)
MX (1) MX2023015076A (cg-RX-API-DMAC7.html)
WO (1) WO2022263594A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201915206D0 (en) 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0520527D0 (en) 2005-10-10 2005-11-16 Ge Healthcare Ltd Automated method
EP2053033A1 (en) * 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
AU2011213568B2 (en) 2010-02-08 2016-05-12 Lantheus Medical Imaging, Inc. Methods and apparatus for synthesizing imaging agents, and intermediates thereof
EP2657213A1 (en) * 2012-04-24 2013-10-30 Institut National de la Santé et de la Recherche Medicale Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors
DK2880005T3 (en) * 2012-07-30 2016-07-18 Univ Denmark Tech Dtu RADIO FLUOR RING PROCEDURE
WO2016086036A2 (en) * 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Methods and compositions for 18f-radiolabeling of biologics
US10716869B2 (en) * 2016-02-29 2020-07-21 Oncodesign Sa Radiolabeled macrocyclic EGFR inhibitor
ES2907130T3 (es) * 2017-09-26 2022-04-22 Inst Nat Sante Rech Med Darapladib radiomarcado, análogos del mismo y su uso como compuestos para la obtención de imágenes
GB201805253D0 (en) * 2018-03-29 2018-05-16 Ge Healthcare Ltd Ip Solid phase extraction

Also Published As

Publication number Publication date
AU2022294052A1 (en) 2023-12-14
EP4355715A1 (en) 2024-04-24
GB202108605D0 (en) 2021-07-28
KR20240021888A (ko) 2024-02-19
IL308917A (en) 2024-01-01
US20250312494A1 (en) 2025-10-09
CA3223802A1 (en) 2022-12-22
BR112023026514A2 (pt) 2024-03-05
WO2022263594A1 (en) 2022-12-22
JP2024522770A (ja) 2024-06-21
US20240366808A1 (en) 2024-11-07
CN117500773A (zh) 2024-02-02

Similar Documents

Publication Publication Date Title
AU2003264043A1 (en) Method of making mercaptoalkylalkoxysilanes
ATE318175T1 (de) Verfahren und vorrichtung zum gleichzeitigen herstellen von säure und base hoher reinheit
KR850004502A (ko) L-카르니틴 및 그 유도체의 제조방법
CN108689870A (zh) 一种氨甲环酸的制备方法
CN106478431B (zh) 一种合成反式环己二甲胺的方法
CN109748812A (zh) 一种丙氨酸铁络合物添加剂的制备方法
ZA200107763B (en) Process for producing non-proteinogenic L-amino acids by fermentation.
KR102127104B1 (ko) 5-아미노레불린산 또는 그 염의 제조 방법
CN109182406A (zh) 一种l-天门冬氨酸的制备方法
WO2003059889A1 (en) Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same
CN101509022A (zh) 一种提高l-色氨酸提取收率的方法
ES8609208A1 (es) Procedimiento de preparacion de p-aminofenoles
RU2008146193A (ru) Способ получения грамицидина с при глубинном выращивании культуры - продуцента bacillus brevis
WO2006003395A3 (en) Molten salts, method of their production and process for generating hydrogen peroxide
CA2000155A1 (en) Production of pigment compositions
JPS5940823B2 (ja) アミノ酸の製法
ES8308802A1 (es) "un procedimiento mejorado para producir en continuo persulfato de sodio".
Cohen et al. Mercaptan Catalysis in Thermoneutral Free Radical Exchange: R·+ R* H [UNK] rh+ R*·
JPH0730006B2 (ja) トランス−4−シアノシクロヘキサン−1−カルボン酸の製造法
US3804893A (en) Process for the preparation of n-acyldopa
HRP20031004A2 (en) Method for producing an essentially chlorite-free,stable, aqueous chlorine-oxygen solution, the chlorine-oxygen solution obtained by means of said method, and the use of the same
AR016252A1 (es) PROCEDIMIENTO PARA LA PRODUCCIoN DE ÁCIDO TARTÁRICO A PARTIR DE UNA MATERIA PRIMA QUE CONTIENE TARTRATO ÁCIDO DE POTASIO
Micklefield et al. Stereochemical course of malonate decarboxylation in Malonomonas rubra
CN108586365A (zh) 一种高纯度4-甲基苯并三氮唑的制备方法
WO2024002633A1 (en) Method for the production of alpha hydroxy-alkylthio carboxylic acids and derivatives thereof